Evidence map›Paper›PMID 37032359›Full record

ArticleMicrobiome2023

Antibiotic treatment using amoxicillin-clavulanic acid impairs gut mycobiota development through modification of the bacterial ecosystem.

Madeleine Spatz, Gregory Da Costa, Rebecka Ventin-Holmberg, Julien Planchais, Chloé Michaudel, Yazhou Wang, Camille Danne, Alexia Lapiere, Marie-Laure Michel, Kaija-Leena Kolho and 3 more

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Microbiome, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. A Review ofInternational journal of microbiology · 2026
    Review
  7. Article
  8. Review
  9. A Novel Strategy to Mitigate Corynebacterium bovis-Associated Hyperkeratosis in Athymic Nude Mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Human microbiota-associated animal models: a review.Frontiers in cellular and infection microbiology · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Synbiotic ofJournal of microbiology and biotechnology · 2024
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Madeleine SpatzMicalis Institute, INRAE, Université Paris-Saclay, 78352, Jouy-en-Josas, AgroParisTech, France. madeleine.spatz@inrae.fr.
Gregory Da CostaMicalis Institute, INRAE, Université Paris-Saclay, 78352, Jouy-en-Josas, AgroParisTech, France.
Rebecka Ventin-HolmbergFaculty of Medicine, Human Microbiome Research Program, University of Helsinki, 00014, Helsinki, Finland.
Julien PlanchaisMicalis Institute, INRAE, Université Paris-Saclay, 78352, Jouy-en-Josas, AgroParisTech, France.
Chloé MichaudelMicalis Institute, INRAE, Université Paris-Saclay, 78352, Jouy-en-Josas, AgroParisTech, France.
Yazhou WangMicalis Institute, INRAE, Université Paris-Saclay, 78352, Jouy-en-Josas, AgroParisTech, France.
Camille DanneMicalis Institute, INRAE, Université Paris-Saclay, 78352, Jouy-en-Josas, AgroParisTech, France.
Alexia LapiereMicalis Institute, INRAE, Université Paris-Saclay, 78352, Jouy-en-Josas, AgroParisTech, France.
Marie-Laure MichelMicalis Institute, INRAE, Université Paris-Saclay, 78352, Jouy-en-Josas, AgroParisTech, France.
Kaija-Leena KolhoFaculty of Medicine, Human Microbiome Research Program, University of Helsinki, 00014, Helsinki, Finland.
Philippe LangellaMicalis Institute, INRAE, Université Paris-Saclay, 78352, Jouy-en-Josas, AgroParisTech, France.
Harry SokolMicalis Institute, INRAE, Université Paris-Saclay, 78352, Jouy-en-Josas, AgroParisTech, France.
Mathias L RichardMicalis Institute, INRAE, Université Paris-Saclay, 78352, Jouy-en-Josas, AgroParisTech, France. mathias.richard@inrae.fr.
AgroParisTech · FRUniversity of Helsinki · FIInserm · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEffects of antibiotics on gut bacteria have been widely studied, but very little is known about the consequences of such treatments on the fungal microbiota (mycobiota). It is commonly believed that fungal load increases in the gastrointestinal tract following antibiotic treatment, but better characterization is clearly needed of how antibiotics directly or indirectly affect the mycobiota and thus the entire microbiota.

designWe used samples from humans (infant cohort) and mice (conventional and human microbiota-associated mice) to study the consequences of antibiotic treatment (amoxicillin-clavulanic acid) on the intestinal microbiota. Bacterial and fungal communities were subjected to qPCR or 16S and ITS2 amplicon-based sequencing for microbiota analysis. In vitro assays further characterized bacterial-fungal interactions, with mixed cultures between specific bacteria and fungi.

resultsAmoxicillin-clavulanic acid treatment triggered a decrease in the total fungal population in mouse feces, while other antibiotics had opposite effects on the fungal load. This decrease is accompanied by a total remodelling of the fungal population with the enrichment in Aspergillus, Cladosporium, and Valsa genera. In the presence of amoxicillin-clavulanic acid, microbiota analysis showed a remodeling of bacterial microbiota with an increase in specific bacteria belonging to the Enterobacteriaceae. Using in vitro assays, we isolated different Enterobacteriaceae species and explored their effect on different fungal strains. We showed that Enterobacter hormaechei was able to reduce the fungal population in vitro and in vivo through yet unknown mechanisms.

conclusionsBacteria and fungi have strong interactions within the microbiota; hence, the perturbation initiated by an antibiotic treatment targeting the bacterial community can have complex consequences and can induce opposite alterations of the mycobiota. Interestingly, amoxicillin-clavulanic acid treatment has a deleterious effect on the fungal community, which may have been partially due to the overgrowth of specific bacterial strains with inhibiting or competing effects on fungi. This study provides new insights into the interactions between fungi and bacteria of the intestinal microbiota and might offer new strategies to modulate gut microbiota equilibrium. Video Abstract.

Indexed as

Amoxicillin-Potassium Clavulanate CombinationMicrobiotaAnimalsAnti-Bacterial AgentsBacteriaFungiGastrointestinal TractHumansMiceAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsAntibioticsEnterobacteriaceaeMicrobiotaMycobiota

Identifiers

PMID37032359
PMCPMC10084673
OpenAlexW4362736352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.